Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Butyric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valeric Acid SCHEMBL27767030 | 0.90 | ALDH1A1 (0.48) | KMT2AALDH1A1KEAP1NFE2L2LMNA | |
| Succinic Acid SCHEMBL27928187 | 0.89 | KMT2A (0.53) | KMT2AALDH1A1KEAP1NFE2L2L3MBTL1 | |
| Succinic Acid SCHEMBL27928188 | 0.89 | KMT2A (0.53) | KMT2AALDH1A1KEAP1NFE2L2L3MBTL1 | |
| Succinic Acid SCHEMBL11462893 | 0.89 | KMT2A (0.53) | KMT2AALDH1A1KEAP1NFE2L2L3MBTL1 | |
| Valeric Acid SCHEMBL14635601 | 0.88 | ALDH1A1 (0.47) | KMT2AALDH1A1KEAP1NFE2L2LMNA | |
| Hexanoate SCHEMBL8208200 | 0.88 | AKR1B1 (0.52) | KMT2AALDH1A1LMNAMAPTTDP1 | |
| Adipic Acid SCHEMBL5313716 | 0.87 | ALDH1A1 (0.50) | KMT2AALDH1A1KEAP1NFE2L2L3MBTL1 | |
| Glutarate SCHEMBL31490757 | 0.87 | KMT2A (0.49) | KMT2AALDH1A1KEAP1NFE2L2L3MBTL1 | |
| Propionic Acid SCHEMBL5147167 | 0.87 | KEAP1 (0.49) | KMT2AALDH1A1KEAP1NFE2L2L3MBTL1 | |
| Undecanoate SCHEMBL7057712 | 0.87 | GPR84 (0.53) | KMT2AALDH1A1MAPTTDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207410-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | NEURODERM, LTD. (IL) | 2024-06-27 | — | — | US | disclosed |
| EP-4305049-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | Neuroderm Ltd (IL) | 2024-01-17 | — | — | EP | disclosed |
| US-11844754-B2 | Methods for treatment of Parkinson's disease | NEURODERM, LTD. (IL) | 2023-12-19 | — | — | US | disclosed |
| CN-116964069-A | Stabilized liquid compositions comprising levodopa-tyrosine conjugates and uses thereof | 纽罗德姆有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-20230157985-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEURODERM, LTD. (IL) | 2023-05-25 | — | — | US | disclosed |
| EP-4025200-A1 | LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF | Neuroderm Ltd (IL) | 2022-07-13 | — | — | EP | disclosed |
| CN-114727973-A | Liquid compositions comprising L-dopa amino acid conjugates and uses thereof | 纽罗德姆有限公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021044420-A1 | LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF | NEURODERM, LTD. (IL) | 2021-03-11 | — | — | WO | disclosed |
| CN-106132972-B | Phosphoramidate for treating HCV infection | 银杏树药业(苏州)有限公司 | 2018-08-31 | — | — | CN | disclosed |
| EP-0187524-B1 | A DIARYL BUTYRIC ACID DERIVATIVE AND THE PRODUCTION PROCESS THEREOF | SUNTORY LIMITED (JP) | 1992-07-29 | — | — | EP | disclosed |
| US-4766116-A | NERVOUS SYSTEM DISORDERS | SUNTORY LIMITED (JP) | 1988-08-23 | — | — | US | disclosed |
| EP-0187524-A2 | A diaryl butyric acid derivative and the production process thereof | SUNTORY LIMITED (JP) | 1986-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11844754-B2 | Methods for treatment of Parkinson's disease | DDC, DDT, SLC6A3 | KMT2A 1550/4885ALDH1A1 609/4885FFAR3 2930/4885 |
| US-20240207410-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | COMT, TH, DDT | KMT2A 996/4885ALDH1A1 398/4885FFAR3 1490/4885 |
| US-20230157985-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | DDC, DDT, COMT | KMT2A 1561/4885ALDH1A1 590/4885FFAR3 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.